747 studies found for:    "Ovarian epithelial cancer"
Show Display Options
Rank Status Study
1 Suspended Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer
Conditions: Ovarian Mucinous Cystadenocarcinoma;   Ovarian Mucinous Cystadenoma With Proliferating Activity;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Stage IA Fallopian Tube Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IB Fallopian Tube Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IC Fallopian Tube Cancer;   Stage IC Ovarian Epithelial Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Other: quality-of-life assessment;   Drug: carboplatin;   Drug: paclitaxel;   Drug: oxaliplatin;   Drug: capecitabine;   Biological: bevacizumab
2 Completed
Has Results
Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Cancer;   Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Drug: tamoxifen citrate;   Drug: thalidomide;   Other: laboratory biomarker analysis
3 Recruiting A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Condition: Epithelial Ovarian Cancer
Interventions: Drug: CAELYX;   Drug: Topotecan HCl
4 Completed
Has Results
Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Conditions: Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Drug: cisplatin;   Drug: alvocidib;   Drug: cisplatin/flavopiridol
5 Active, not recruiting Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Conditions: Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Biological: bevacizumab;   Procedure: therapeutic conventional surgery;   Procedure: computed tomography
6 Recruiting Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma
Conditions: Ovarian Neoplasms;   Ovarian Epithelial Cancer
Interventions: Biological: DCVAC/OvCa with Standard of Care;   Biological: DCVAC/OvCa sequentially chemotherapy;   Drug: Standard of Care
7 Active, not recruiting Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Biological: bevacizumab;   Drug: cisplatin;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
8 Recruiting Safety, Feasibility and Effect of TTFields Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma
Condition: Ovarian Carcinoma
Interventions: Device: NovoTTF-100L(O);   Drug: Paclitaxel
9 Recruiting Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy
Conditions: Ovarian Carcinoma;   Fallopian Tube Carcinoma;   Primary Peritoneal Carcinoma
Intervention: Procedure: HIPEC
10 Unknown  Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study
Condition: Ovarian Carcinoma
Intervention: Other: timing of surgery
11 Active, not recruiting A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma
Conditions: Ovarian Carcinoma;   Relapse
Interventions: Drug: Oxaliplatin;   Drug: oxaliplatin
12 Completed Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma
Conditions: Ovarian Carcinoma;   Recurrent Endometrial Carcinoma
Intervention: Drug: Tc 99m EC20
13 Withdrawn Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression
Condition: Ovarian Carcinoma
Intervention: Drug: Fondaparinux
14 Completed EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer
Conditions: Primary Peritoneal Cavity Cancer;   Stage I Endometrial Carcinoma;   Stage I Ovarian Epithelial Cancer;   Stage IA Cervical Cancer;   Stage IB Cervical Cancer;   Stage II Endometrial Carcinoma;   Stage II Ovarian Epithelial Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Cervical Cancer;   Stage III Endometrial Carcinoma;   Stage III Ovarian Epithelial Cancer;   Stage IV Endometrial Carcinoma;   Stage IV Ovarian Epithelial Cancer;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer
Intervention: Drug: EF5
15 Completed Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer
Conditions: Epithelial Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Intervention: Dietary Supplement: Early post-operative enteral feeding
16 Active, not recruiting OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
Conditions: Fallopian Tube Cancer;   Primary Peritoneal Cavity Cancer;   Stage I Ovarian Epithelial Cancer;   Stage II Ovarian Epithelial Cancer;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Biological: immunological adjuvant OPT-821;   Biological: polyvalent antigen-KLH conjugate vaccine;   Other: laboratory biomarker analysis
17 Unknown  Study on Neutropenia Induced by Adjuvant Paclitaxel/Carboplatin Chemotherapy in Patients With Epithelial Ovarian Cancer
Condition: Epithelial Ovarian Cancer
Intervention:
18 Withdrawn Whole Abdomen Radiation in Conjunction With Intraperitoneal Chemotherapy for the Treatment of Small Volume Recurrent Ovarian Carcinoma Limited to the Peritoneal Cavity
Condition: Recurrent Ovarian Carcinoma
Interventions: Drug: Cisplatin;   Radiation: Whole Abdomen Radiotherapy
19 Active, not recruiting Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors
Conditions: Fallopian Tube Cancer;   Primary Peritoneal Cavity Cancer;   Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor;   Recurrent Ovarian Epithelial Cancer;   Stage III Borderline Ovarian Surface Epithelial-stromal Tumor;   Stage III Ovarian Epithelial Cancer;   Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor;   Stage IV Ovarian Epithelial Cancer
Intervention: Drug: belinostat
20 Withdrawn Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy
Conditions: Fallopian Tube Cancer;   Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Biological: oregovomab;   Drug: cyclophosphamide;   Procedure: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years